1
|
Zamarbide Losada JN, Sulpice E, Combe S, Almeida GS, Leach DA, Choo J, Protopapa L, Hamilton MP, McGuire S, Gidrol X, Bevan CL, Fletcher CE. Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancer. J Endocrinol 2023; 256:e220229. [PMID: 36622663 PMCID: PMC9986394 DOI: 10.1530/joe-22-0229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 01/09/2023] [Indexed: 01/10/2023]
Abstract
Breast cancer (BC) is the most diagnosed cancer in women worldwide. In estrogen receptor (ER)-positive disease, anti-estrogens and aromatase inhibitors (AI) improve patient survival; however, many patients develop resistance. Dysregulation of apoptosis is a common resistance mechanism; thus, agents that can reinstate the activity of apoptotic pathways represent promising therapeutics for advanced drug-resistant disease. Emerging targets in this scenario include microRNAs (miRs). To identify miRs modulating apoptosis in drug-responsive and -resistant BC, a high-throughput miR inhibitor screen was performed, followed by high-content screening microscopy for apoptotic markers. Validation demonstrated that miR-361-3p inhibitor significantly increases early apoptosis and reduces proliferation of drug-responsive (MCF7), plus AI-/antiestrogen-resistant derivatives (LTED, TamR, FulvR), and ER- cells (MDA-MB-231). Importantly, proliferation-inhibitory effects were observed in vivo in a xenograft model, indicating the potential clinical application of miR-361-3p inhibition. RNA-seq of tumour xenografts identified FANCA as a direct miR-361-3p target, and validation suggested miR-361-3p inhibitor effects might be mediated in part through FANCA modulation. Moreover, miR-361-3p inhibition resulted in p53-mediated G1 cell cycle arrest through activation of p21 and reduced BC invasion. Analysis of publicly available datasets showed miR-361-3p expression is significantly higher in primary breast tumours vspaired normal tissue and is associated with decreased overall survival. In addition, miR-361-3p inhibitor treatment of BC patient explants decreased levels of miR-361-3p and proliferation marker, Ki67. Finally, miR-361-3p inhibitor showed synergistic effects on BC growth when combined with PARP inhibitor, Olaparib. Together, these studies identify miR-361-3p inhibitor as a potential new treatment for drug-responsive and -resistant advanced BC.
Collapse
Affiliation(s)
- J N Zamarbide Losada
- Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK
| | - E Sulpice
- Université Grenoble Alpes, CEA, INSERM, BIG, BGE, Grenoble, France
| | - S Combe
- Université Grenoble Alpes, CEA, INSERM, BIG, BGE, Grenoble, France
| | - G S Almeida
- Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK
| | - D A Leach
- Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK
| | - J Choo
- Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK
| | - L Protopapa
- Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK
| | - M P Hamilton
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA
| | - S McGuire
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA
| | - X Gidrol
- Université Grenoble Alpes, CEA, INSERM, BIG, BGE, Grenoble, France
| | - C L Bevan
- Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK
| | - C E Fletcher
- Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK
| |
Collapse
|
2
|
Rossi B, Blanche P, Roussel-Robert V, Berezné A, Combe S, Coppo P, Guillevin L, Le Jeunne C, Mouthon L, Ounnoughene N, Stieltjes N, Groh M. Rituximab as first-line therapy for acquired haemophilia A: a single-centre 10-year experience. Haemophilia 2016; 22:e338-41. [DOI: 10.1111/hae.12973] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/01/2016] [Indexed: 11/28/2022]
Affiliation(s)
- B. Rossi
- Department of Internal Medicine; National Referral Center for Rare Autoimmune and Systemic Diseases; Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes; Paris France
| | - P. Blanche
- Department of Internal Medicine; National Referral Center for Rare Autoimmune and Systemic Diseases; Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes; Paris France
| | - V. Roussel-Robert
- Centre des hémophiles; Hôpital Cochin, Assistance Publique Hôpitaux de Paris Université Paris Descartes; Paris France
| | - A. Berezné
- Department of Internal Medicine; National Referral Center for Rare Autoimmune and Systemic Diseases; Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes; Paris France
| | - S. Combe
- Centre des hémophiles; Hôpital Cochin, Assistance Publique Hôpitaux de Paris Université Paris Descartes; Paris France
| | - P. Coppo
- Department of Hematology; Hôpital Saint-Antoine, Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie; Paris France
| | - L. Guillevin
- Department of Internal Medicine; National Referral Center for Rare Autoimmune and Systemic Diseases; Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes; Paris France
| | - C. Le Jeunne
- Department of Internal Medicine; National Referral Center for Rare Autoimmune and Systemic Diseases; Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes; Paris France
| | - L. Mouthon
- Department of Internal Medicine; National Referral Center for Rare Autoimmune and Systemic Diseases; Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes; Paris France
| | - N. Ounnoughene
- Centre des hémophiles; Hôpital Cochin, Assistance Publique Hôpitaux de Paris Université Paris Descartes; Paris France
| | - N. Stieltjes
- Centre des hémophiles; Hôpital Cochin, Assistance Publique Hôpitaux de Paris Université Paris Descartes; Paris France
| | - M. Groh
- Department of Internal Medicine; National Referral Center for Rare Autoimmune and Systemic Diseases; Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes; Paris France
| |
Collapse
|
3
|
Gueret P, Combe S, Krezel C, Fuseau E, van Giersbergen PLM, Petitou M, Neuhart E. First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action. Eur J Clin Pharmacol 2016; 72:1041-50. [DOI: 10.1007/s00228-016-2077-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2016] [Accepted: 05/27/2016] [Indexed: 10/21/2022]
|
4
|
Combe S, Büller HR. [New treatments for venous thromboembolic disease]. J Mal Vasc 2011; 36 Suppl 1:S16-S19. [PMID: 22177764 DOI: 10.1016/s0398-0499(11)70003-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Following the landmark study by Barritt and Jordan in 1960, in which patients with venous thromboembolism (VTE) were randomized to no treatment or a combination of heparin and warfarin, antithrombotic therapy for this disease became widely accepted. This study was stopped prematurely because half of the non-treated patients had recurrent pulmonary embolism (PE), or died. It was subsequently found that after a VTE, patients given warfarin alone had a 3-4-fold higher incidence of recurrent VTE than patients given both heparin and warfarin. Since the 1990 s, standard therapy for VTE has comprised an initial 5-7 day course of parenteral anticoagulant plus warfarin continued for at least 3 months. Recently, several orally active small molecules have been evaluated in the treatment of VTE, including a direct thrombin inhibitor and direct Factor Xa inhibitors. Other novel oral agents are also in development for VTE treatment. Although the DTI ximelagatran, the first oral agent to be introduced since warfarin was withdrawn from the market in Europe because of hepatotoxicity, evidence from clinical trial evaluating other single target-specific oral agents in the treatment of VTE is encouraging. It is therefore likely that use of warfarin in the treatment and secondary prevention of VTE will decrease should these novel oral agents be introduced for these indications. Additionally, there will be less distinction between initial and long-term therapy, and a great majority of patients will be treated on an outpatient basis for prolonged periods of time. Recently these expectations were fulfilled by the results of two Phase III studies in patients with VTE. The Recover I study indicated that Dabigatran (150 mg b.d.) following an initial course of LMWH was non-inferior to the standard treatment of LMWH plus warfarin, with also a similar safety profile. The Einstein DVT study revealed that Rivaroxaban as a single agent can safely replace the standard treatment in patients with DVT. Taken together these studies and a few others that have or are about to be completed will indeed introduce a paradigm shift in the way patients with VTE will be treated.
Collapse
Affiliation(s)
- S Combe
- Groupe Hospitalier Cochin/Broca/Hôtel-Dieu, 27 rue du Faubourg Saint-Jacques, 75679 Paris cedex 14, France.
| | | |
Collapse
|
5
|
Samamaa MM, Conard J, Flaujac C, Combe S, Horellou MH. Hétérogénéité pharmacologique des nouveaux anticoagulants. ACTA ACUST UNITED AC 2011; 36 Suppl 1:S10-5. [DOI: 10.1016/s0398-0499(11)70002-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Fouqué B, Schaack B, Obeïd P, Combe S, Gétin S, Barritault P, Chaton P, Chatelain F. Multiple wavelength fluorescence enhancement on glass substrates for biochip and cell analyses. Biosens Bioelectron 2005; 20:2335-40. [PMID: 15797336 DOI: 10.1016/j.bios.2004.08.009] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2004] [Revised: 07/27/2004] [Accepted: 08/04/2004] [Indexed: 10/26/2022]
Abstract
In microarrays experiments, a serious limitation is the unreliability of low signal intensities data and the lack of reproducibility for the resulting ratios between samples and controls. Most of the light emitted by a fluorophore at the air/glass interface of a glass slide is absorbed by the glass so just a part of the emitted fluorescence is detected. To improve the sensitivity of the fluorescence detection of both common fluorophores Cy3 and Cy5 in DNA microarrays and fluorescent cell analyses, we have designed a multi layer mirror with alternative thin layers of SiO2 and HfO2. This mirror (MOTL) prevents fluorescence absorption, allows the simultaneous enhancement of the fluorescence signals and increases the dynamic range of the slides. Using MOTL slides, Cy3 and Cy5 intensities are enhanced by 5-8-fold, consequently, the fluorescence analysis becomes easier and should allow the detection of low copy number genes or weakly fluorescent cells. With the same approach, other multiple optical thin layer slides could be designed for other series of fluorophores, extending the field of their applications.
Collapse
Affiliation(s)
- B Fouqué
- CEA/Direction des Sciences du Vivant DRDC/Biopuces, 17 rue de Martyrs, 38054 Grenoble Cedex 9, France.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Catella-Lawson F, Kapoor S, Moretti D, De Marco S, Vigilante GJ, Cucchiara AJ, Ramsey KE, Combe S, Rocca B, Theroux P, FitzGerald GA. Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease. Am J Cardiol 2001; 88:236-42. [PMID: 11472700 DOI: 10.1016/s0002-9149(01)01632-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Dose-finding studies and trials of interaction of oral glycoprotein IIb/IIIa antagonists with other antiplatelet agents have been limited. We hypothesized that these detailed assessments could be first performed in patients with stable coronary artery disease (CAD) and then extrapolated to the target population. To this end, we performed 2 sequential studies. The first study examined the dose-related effects on indexes of platelet and vascular function induced by the oral inhibitor RPR 109891, when given alone and in combination with aspirin, in patients (n = 100) with stable CAD. The second study (the Antagonism of the FIbrinogen Receptor after Myocardial Events trial) assessed the pharmacodynamics and safety of derived regimens in patients (n = 320) with unstable coronary syndromes. In patients with stable CAD, platelet aggregation was dose dependently inhibited by RPR 109891, and the dose-response relation was shifted to the right by the concomitant administration of aspirin (p = 0.0001). The degree of platelet inhibition induced by 3 doses of RPR 109891 (plus aspirin) was lower in patients with unstable than stable CAD. No drug-related major bleeding occurred in either study. RPR 109891 treatment was associated with acute and delayed thrombocytopenia. In conclusion, chronic treatment with an oral glycoprotein IIb/IIIa antagonist (1) induces antiplatelet effects that are potentiated by concomitant administration of aspirin, (2) may require dose adjustment in syndromes of platelet activation, (3) is associated with a low rate of clinically significant bleeding when doses inducing incomplete inhibition of platelet aggregation are used, and (4) requires frequent monitoring of platelet count unless reliable predictors of delayed thrombocytopenia become available.
Collapse
Affiliation(s)
- F Catella-Lawson
- EUPenn Group of Investigators at the Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Samama CM, Combe S, Ill P, Barre E, Dreux S, Viars P. Are low-molecular-weight heparins useful for the prophylaxis and treatment of arterial thrombi? Haemostasis 1996; 26 Suppl 2:57-64. [PMID: 8707168 DOI: 10.1159/000217273] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The pharmacologic specificity of low-molecular-weight heparins (LMWHs) has enabled multiple attractive developments in the prophylaxis and treatment of arterial thrombosis. Their high antithrombotic potency associated with a potentially lower induced bleeding risk, the lack of platelet interaction, the prevention of myointimal hyperplasia, and the lower incidence of heparin-induced thrombocytopenia, are major advantages. New studies in cardiology and vascular surgery demonstrate a high efficacy for LMWHs associated with a low risk.
Collapse
Affiliation(s)
- C M Samama
- Département d'Anesthésie-Réanimation Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | | | | | | | | | | |
Collapse
|
9
|
Hadjez J, Combe S, Horellou M, Conard J, Nguyen G, Van Dreden P, Samama M. Heterogeneous mechanisms responsible for reduced fibrinolytic capacity in patients with a history of venous thrombosis. ACTA ACUST UNITED AC 1994. [DOI: 10.1016/s0268-9499(05)80024-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Farkas JC, Chapuis C, Combe S, Silsiguen M, Marzelle J, Laurian C, Cormier JM. A randomised controlled trial of a low-molecular-weight heparin (Enoxaparin) to prevent deep-vein thrombosis in patients undergoing vascular surgery. Eur J Vasc Surg 1993; 7:554-60. [PMID: 8405501 DOI: 10.1016/s0950-821x(05)80369-x] [Citation(s) in RCA: 55] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The incidence of postoperative deep vein thrombosis (PDVT) after aortic surgery and lower limb revascularisation has not been assessed by a large prospective study. In a prospective randomised trial the effect of a low-molecular-weight heparin fragment, Enoxaparin (ENX) 4200 anti factor Xa IU once daily was compared to that of unfractionated heparin (UFH) 7500 IU twice daily. Two hundred and thirty-three consecutive patients were classified into three groups, aortic or aortoiliac and aneurysmectomy (n = 75), aorto-femoral bypass for atherosclerotic disease (n = 71), and femoropopliteal or femorodistal bypass (n = 87). Patients were analysed for development of deep vein thrombosis by Duplex scanning and, if positive, by venography between the seventh and tenth postoperative day. PDVT was present in 10 patients in the ENX group and in four patients in the UFH group (8.2 and 3.6% respectively, NS). The incidence of PDVT was 8% after aortic or aortoiliac aneurysmectomy, 7% after aortofemoral revascularisation, and 3.4% after femoropopliteal or femorodistal bypass. The overall incidence of PDVT after aortic surgery was 7.5% (95% CI 5.4-9.7). There was no pulmonary embolism. Intra-operative blood loss and postoperative bleeding events did not differ significantly between the ENX and UFH groups. After 1 month follow-up, no clinical event or death could be related to PDVT or pulmonary embolism. In conclusion, in vascular surgery ENX is as safe and effective in the prevention of PDVT as is UFH.
Collapse
Affiliation(s)
- J C Farkas
- Department of Vascular Surgery, Hôpital Saint-Joseph, Paris, France
| | | | | | | | | | | | | |
Collapse
|
11
|
Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, Silsiguen M, Combe S. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993; 153:1541-6. [PMID: 8391792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
BACKGROUND A low-molecular-weight heparin, enoxaparin sodium, has been shown to be effective and safe in preventing deep vein thrombosis both in general surgery and in high-risk orthopedic surgery. We conducted a controlled, randomized trial with enoxaparin in the treatment of established deep vein thrombosis. METHODS In a multicenter trial, we compared fixed-dose subcutaneous enoxaparin, given twice daily, with adjusted-dose intravenous unfractionated heparin (UFH) given by continuous intravenous infusion for the initial 10 days of treatment of patients with proximal vein thrombosis. The primary efficacy outcome was the change of the size of the thrombus assessed by repeated venograms between day 0 and day 10. The primary analysis of safety was based on the incidence of major bleeding during 10 days of treatment. RESULTS There were 67 patients in each group. Venographic assessment of clot size evolution between day 0 and day 10 showed a statistically significant superiority (P < .002) of enoxaparin over the reference treatment with UFH. Moreover, the incidence of overall recurrent thromboembolic events during 10 days of treatment was significantly higher (P < .002) in the UFH group (seven of 67) than in the enoxaparin group (one of 67). There were no serious bleeding complications in either group. CONCLUSIONS Enoxaparin is at least as effective and safe as UFH under the conditions of this study. Moreover, it is more comfortable for patients and less time-consuming for nurses and laboratories. Thus, our study confirmed, with the use of enoxaparin, other observations that low-molecular-weight heparin provides a real therapeutic advance in the treatment of deep vein thrombosis.
Collapse
Affiliation(s)
- G Simonneau
- Department of Pneumology and Intensive Care Medicine, Antoine Béclère Hospital, Clamart, France
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
It has been recently shown that platelet-rich thrombi are particularly resistant to thrombolysis. Since unfractionated heparin was reported to enhance fibrinogen binding to platelets responsible for the hyperaggregating effect of this drug, the purpose of this work was to determine whether or not heparin could also modulate platelet interaction to whole blood clot. We have therefore investigated the retention to a standard clot of 111In-labelled platelets suspended in plasma in presence of saline (control), heparin or a low molecular weight heparin (Enoxaparin). We have shown that the platelet interaction to the clot was significantly increased by heparin but not by enoxaparin used at the same anti Xa activity. In conclusion, this difference may favor the use of enoxaparin over heparin in clinical situation associated with platelet retention to fibrin clot, such as thrombolysis.
Collapse
Affiliation(s)
- M Mirshahi
- Laboratoire Sainte Marie, Hôtel Dieu, Paris, France
| | | | | | | | | | | | | |
Collapse
|
13
|
Samama CM, Barre E, Combe S, Dreux S, Kieffer E, Viars P. A pilot study on the use of a low molecular weight heparin (Enoxaparin) in arterial reconstructive surgery. Semin Thromb Hemost 1991; 17:367-70. [PMID: 1666457 DOI: 10.1055/s-2007-1002636] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- C M Samama
- Département d'Anesthésie-Réanimation, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | | | | | | | | | | |
Collapse
|
14
|
Samama MM, Combe S, Horellou MH, Augras D, Truc JB, Conard J, Girard P, Bara L, Poitout P. Anti Xa activity and prothrombinase inhibition in patients treated with two different doses of enoxaparin in gynecologic surgery. Thromb Res Suppl 1991; 14:29-37. [PMID: 1658968 DOI: 10.1016/0049-3848(91)90401-h] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A prospective open study was performed in a series of 547 patients undergoing gynecologic surgery. A dose of 20 mg of enoxaparin was administered to all patients 2 hours before surgery. Then patients at high risk of thrombosis (mostly oncologic surgery) received 40 mg of enoxaparin daily whereas those at moderate risk received 20 mg of enoxaparin daily. The principal aim of this prospective open study was to monitor amidolytic anti Xa activity and to study the inhibition of intrinsic prothrombinase using prothrombin consumption measurement as a simple and global test. A second aim was to investigate efficacy and tolerance of these regimens. Treatment tolerance was satisfactory with both regimens since the total incidence of bleeding was 1.8%. A single patient developed a clinically significant thrombosis during hospital stay. The results confirm and extend previous reports regarding a dose effect relationship between the dose of Enoxaparin and plasma Anti Xa activity 3 hours after s.c. injection. A significant relationship was found between Anti Xa activity and patients body weight. Interestingly a dose dependent inhibition of intrinsic prothrombinase was observed when using a one stage prothrombin consumption assay in whole blood. This test in whole blood can be considered as closer to physiological conditions than assays performed in citrated platelet rich or platelet poor plasma samples. The mechanism of intrinsic prothrombinase inhibition during prophylactic treatment with enoxaparin requires further investigation.
Collapse
Affiliation(s)
- M M Samama
- Laboratoire Central d'Hématologie, Hôtel-Dieu, Paris
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Samama CM, Mouren S, Bridel MP, Combe S, Koskas F, Kieffer E, Viars P. [Peri- and postoperative use of low molecular weight heparin in peripheral vascular surgery]. Ann Fr Anesth Reanim 1990; 9:102-5. [PMID: 2163591 DOI: 10.1016/s0750-7658(05)80046-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A pilot study has been conducted in ten consecutive patients undergoing femoro-popliteal reconstruction or distal vascular surgery under epidural anaesthesia. Immediately before arterial cross-clamping, enoxaparin (E) (75 anti-Xa IU.kg-1) was injected intravenously (i.v.). During surgery, washing of the saphenous or polytetrafluoroethylene (PTFE) graft has been performed using enoxaparin. Enoxaparin (75 anti-Xa IU.kg-1) was administered subcutaneously (S.C.) 8 hours after the i.v. injection, and then every 12 hours during 10 days. The patency of the vascular reconstruction and the side-effects of E administration were evaluated clinically before and during surgery, then by a daily clinical examination. Echo-Doppler and/or arteriography were also performed preoperatively and on the 10th postoperative day. Haematocrit, platelet count, activated partial thromboplastin time, prothrombin time, thrombin time, fibrinogen and anti-Xa activity were assessed. None of the patients developed venous or arterial thrombosis and all the by-pass grafts remained patient. Only one minor surgical bleeding occurred on the first post operative day, despite anti-Xa levels in the expected range. One patient developed minor haematomas at the injection site. No bleeding was observed. Further randomized studies comparing LMWH and UH are required in order to substantiate these preliminary clinical and biological findings.
Collapse
Affiliation(s)
- C M Samama
- Service d'Anesthésie-Réanimation, Groupe Hospitalier Pitié-Salpêtrière, Paris
| | | | | | | | | | | | | |
Collapse
|
16
|
Marzelle J, Combe S, Gigou F, Samama M. Results of thrombolysis in the treatment of arterial ischemia of the limbs according to mode of administration. INT ANGIOL 1989; 8:179-87. [PMID: 2699481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
After reviewing the principles, results and complications of thrombolytic therapy with "classical" agents (Streptokinase and Urokinase) used via intravenous, intraarterial route, or intraoperatively, and with more "modern" agents (APSAC, scuPA, tPA), we discuss the future of thrombolysis in the treatment of arterial ischemia of the limbs. Several items need to be clarified: --indication of thrombolysis among other treatments, mainly surgery, of arterial ischemia depends on the clinical staging of ischemia, its causes and the site of arterial obstruction; --method of delivery of the thrombolytic agent must provide the highest local concentration and the lowest systemic side effects; --efficacy of each thrombolytic agent must be analyzed when used in peripheral arterial ischemia, but also in other diseases such as myocardial infarction.
Collapse
Affiliation(s)
- J Marzelle
- Service de Chirurgie Vasculaire, Hopital Saint-Joseph, Paris
| | | | | | | |
Collapse
|
17
|
Combe S. [Patients who disturb...]. Rev Infirm 1983; 33:54-7. [PMID: 6551995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/05/2023]
|